Treatment of systemic effects in patients with COPD
- Conditions
- Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reverible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking.
- Registration Number
- EUCTR2006-000978-68-NL
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
50 clinically stable COPD patients (GOLD II, III, IV) with a low fat-free mass (<16 kg×m-2 in ? and <15 kg×m-2 in ?) and, 50 healthy volunteers.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Exacerbation <2 months prior the start of the experiment
Smoking
Oral corticosteriods
Long-term oxigen therapy
Respiratory insufficiency (PaO2 <8 kPa)
(PaCO2 > 6.3 kPa)
Other chronic/exercise limiting disorders
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method